Terms: = Cervical cancer AND IL7R, P16871, IL-7R-alpha, CDW127, CD127, ENSG00000168685, 3575 AND Treatment
3 results:
1. Immune correlates of clinical benefit in a phase I study of hyperthermia with adoptive T cell immunotherapy in patients with solid tumors.
Qiao G; Wang X; Zhou X; Morse MA; Wu J; Wang S; Song Y; Jiang N; Zhao Y; Zhou L; Zhao J; Di Y; Zhu L; Hobeika A; Ren J; Lyerly HK
Int J Hyperthermia; 2019 Nov; 36(sup1):74-82. PubMed ID: 31795830
[No Abstract] [Full Text] [Related]
2. Up-regulation of inflammation-related LncRNA-il7r predicts poor clinical outcome in patients with cervical cancer.
Fan Y; Nan Y; Huang J; Zhong H; Zhou W
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29720427
[TBL] [Abstract] [Full Text] [Related]
3. Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer.
Sugiyama T; Yakushiji M; Noda K; Ikeda M; Kudoh R; Yajima A; Tomoda Y; Terashima Y; Takeuchi S; Hiura M; Saji F; Takahashi T; Umesaki N; Sato S; Hatae M; Ohashi Y
Oncology; 2000; 58(1):31-7. PubMed ID: 10644938
[TBL] [Abstract] [Full Text] [Related]
